Cardiac amyloidosis is an often-missed, life-threatening cause of heart failure. As new disease-modifying therapies emerge, timely and earlier diagnosis is critical. EchoGo® Amyloidosis is the first ...
Please provide your email address to receive an email when new articles are posted on . An AI model accurately distinguished cardiac amyloidosis from other phenotypic mimics. The model also showed ...
ROCHESTER, Minn. — An artificial intelligence (AI) model developed by Mayo Clinic and Ultromics, Ltd., an AI echocardiography company based in Oxford, England, is highly accurate in screening for ...
OXFORD, England, Jan. 10, 2024 /PRNewswire/ -- Ultromics, a patient outcomes-focused AI-driven health technology company with roots at the University of Oxford, UK, has entered into an agreement with ...
In a new study published in the European Heart Journal, researchers reported the successful development and validation of a medical artificial intelligence (AI) model that screens for cardiac ...
TCT 421: Unmasking Sex-Based Disparities in Revascularization and Outcomes After Coronary CT Angiography: A Propensity Score Matched Cohort Study. Receive the the latest news, research, and ...
A report from the World Heart Federation provides an overview of transthyretin amyloid cardiomyopathy (ATTR-CM), including tools for diagnosis and patient management, highlighting the importance of ...
Heart failure can be a scary diagnosis. But what if there’s something else going on that’s even harder to spot? Meet transthyretin cardiac amyloidosis (ATTR-CM)—a serious heart condition that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback